Catalyst
Slingshot members are tracking this event:
FDA Designates Immunomedics' (IMMU) IMMU-132 a Breakthrough Therapy for Treatment of Triple Negative Breast Cancer (TNBC)
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| IMMU |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 05, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Immu-132, Braekthrough Therapy Designation, Triple Negative Breast Cancer, Resistant To Therapy
